Results 21 to 30 of about 27,758 (263)
The microRNA landscape of MYCN-amplified neuroblastoma [PDF]
Frontiers in Oncology, 2021 MYCN gene amplification and upregulated expression are major hallmarks in the progression of high-risk neuroblastoma. MYCN expression and function in modulating gene synthesis in neuroblastoma is controlled at virtually every level, including poorly ...
Hagemann, Sven +7 more
core +7 more sources
Regulation of
BMC Cancer, 2009 Background Amplification of the MYCN gene in neuroblastoma (NB) is associated with a poor prognosis. However, MYCN-amplification does not automatically result in higher expression of MYCN in children with NB.
de Vries I +7 more
doaj +3 more sources
PLoS BiologyMYCN activates canonical MYC targets involved in ribosome biogenesis, protein synthesis, and represses neuronal differentiation genes to drive oncogenesis in neuroblastoma (NB). How MYCN orchestrates global gene expression remains incompletely understood.
Zhihui Liu +7 more
doaj +2 more sources
MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
Oncotarget, 2018 The MYC oncogenes and p53 have opposing yet interrelated roles in normal development and tumorigenesis. How MYCN expression alters the biology and clinical responsiveness of pediatric neuroblastoma remains poorly defined.
Shohet, Jason M. +19 more
core +5 more sources
Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy [PDF]
Pharmacological ResearchCurrent treatment protocols have limited success against MYCN-amplified neuroblastoma. Adoptive T cell therapy presents an innovative strategy to improve cure rates.
Laura Grunewald +22 more
doaj +2 more sources
Frontiers in Oncology, 2013 It is well known that Neuroblastoma (NB) patients whose tumors have an undifferentiated histology and a transcriptome enriched in cell cycle genes have a worse prognosis. This contrasts with the good prognoses of patients whose tumors have histologic evidence of differentiation and a transcriptome enriched in differentiation genes.
He, Stanley +3 more
openaire +3 more sources
LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma
EMBO Molecular Medicine, 2023 Ferroptosis has emerged as an attractive strategy in cancer therapy. Understanding the operational networks regulating ferroptosis may unravel vulnerabilities that could be harnessed for therapeutic benefit. Using CRISPR‐activation screens in ferroptosis
H. Alborzinia +32 more
semanticscholar +1 more source
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis
Nature Cancer, 2022 Aberrant expression of MYC transcription factor family members predicts poor clinical outcome in many human cancers. Oncogenic MYC profoundly alters metabolism and mediates an antioxidant response to maintain redox balance. Here we show that MYCN induces
H. Alborzinia +38 more
semanticscholar +1 more source
Molecular Cancer, 2023 Background Neuroblastoma is the most common solid tumor in infants accounting for approximately 15% of all cancer-related deaths. Over 50% of high-risk neuroblastoma relapse, emphasizing the need of novel drug targets and therapeutic strategies.
Sven Hagemann +10 more
semanticscholar +1 more source
MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma
Cell Death and Disease, 2021 MYCN amplification is tightly associated with the poor prognosis of pediatric neuroblastoma (NB). The regulation of NB cell death by MYCN represents an important aspect, as it directly contributes to tumor progression and therapeutic resistance. However,
Yu-Xiong Lu +13 more
semanticscholar +1 more source